Company Focus
CellTrion
Latest CellTrion News
Biosimilars
The US Food and Drug Administration (FDA) has approved an expanded indication of the intravenous (IV) formulation of South Korean firm Celltrion’ Avtozma (tocilizumab-anoh) to include the treatment of cytokine release syndrome (CRS) in adults and pediatric patients aged two years and older. 6 August 2025
Related News
Insights
Company Spotlight
A biopharmaceutical company focused on developing tumor infiltrating lymphocyte (TIL) therapies for patients with cancer.
Latest News & Features of interest to CellTrion
Pharmaceutical
The Swiss government has met with senior executives from Roche and Novartis to discuss the outlook for the pharmaceutical industry amid escalating US trade measures. 15 August 2025
Pharmaceutical
The US Department of Health and Human Services has reinstated the Task Force on Safer Childhood Vaccines, a panel created by Congress to strengthen the safety, quality and oversight of vaccines given to American children. The original group was disbanded in 1998. 15 August 2025
Pharmaceutical
A first-of-its-kind study from UK pharm major AstraZeneca and Macmillan Cancer Support into the barriers around access to the latest biomarker testing for cancer in the UK has been published in Future Oncology. 15 August 2025
Biotechnology
Pilatus Biosciences, a US biopharmaceutical company developing novel metabolic checkpoint immunotherapies for liver and gastrointestinal cancers, today announced a clinical trial collaboration with Swiss pharma giant Roche. 14 August 2025
Biotechnology
Danish clinical-stage techbio, Evaxion, which is specializing in developing AI-Immunology powered vaccines, today provided a business update. 14 August 2025
Pharmaceutical
China-based RNA therapeutics developer Ribopeutic has raised close to 100 million yuan ($13.9 million) in pre-A financing, with Tasly Holding Group and Pan-Lin Asset Management leading the round. 14 August 2025
Biotechnology
Maryland, USA-based biotech MacroGenics announced that effective as of August 13, 2025, Eric Risser has been appointed president, chief executive (CEO) and to the board of directors. 14 August 2025
Biotechnology
US biotech Vedanta Biosciences has abandoned development of its ulcerative colitis candidate VE202 after the bacterial cocktail failed to outperform placebo in a mid-stage trial. 14 August 2025
Pharmaceutical
Danish CNS specialist Lundbeck has reported revenue grew 14% at constant exchange rates (CER), plus 14% DKK, to 12,258 million kroner ($1,915 million) in the first six months of 2025. Growth in the USA and Europe was the driver of this strong performance. 14 August 2025
Biotechnology
Sino-American biotech BeOne Medicines has announced financial results from the second quarter of 2025. 13 August 2025
Latest In Brief for CellTrion
Biotechnology
US biotech Genascence today announced the US Food and Drug Administration (FDA) has granted the Regenerative Medicine Advanced Therapy (RMAT) designation to GNSC-001, a potential first-in-class gene therapy blocking interleukin 1 (IL-1) for the treatment of knee osteoarthritis (OA). 16 July 2025
Latest Relevant Ones To Watch News
US specialty pharma business SERB Pharmaceuticals is acquiring Y-mAbs Therapeutics in a $412 million all-cash deal that brings the pediatric cancer drug Danyelza (naxitamab-gqgk) into its rare oncology portfolio. 6 August 2025
28 July 2025
18 July 2025
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze